Next Article in Journal
Glutathione Transferases Superfamily: Cold-Inducible Expression of Distinct GST Genes in Brassica oleracea
Next Article in Special Issue
Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis
Previous Article in Journal
Characterization and Discrimination of Ancient Grains: A Metabolomics Approach
Previous Article in Special Issue
Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2016, 17(8), 1214;

Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy

Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland
Author to whom correspondence should be addressed.
Academic Editor: Chris Jackson
Received: 25 April 2016 / Revised: 6 July 2016 / Accepted: 13 July 2016 / Published: 27 July 2016
(This article belongs to the Special Issue Inflammatory Skin Conditions)
Full-Text   |   PDF [2722 KB, uploaded 27 July 2016]   |  


Acute generalized exanthematous pustulosis (AGEP) is a severe, usually drug-related reaction, characterized by an acute onset of mainly small non-follicular pustules on an erythematous base and spontaneous resolution usually within two weeks. Systemic involvement occurs in about 20% of cases. The course is mostly benign, and only in rare cases complications lead to life-threatening situations. Recent studies highlight the importance of genetic variations in interleukin-36 receptor antagonist gene (IL-36RN) in the pathogenesis of this disease. The physiopathology of AGEP remains unclear, but an involvement of innate and acquired immune cells together with resident cells (keratinocytes), which recruit and activate neutrophils via production of cytokines/chemokines such as IL-17, IL-36, granulocyte-macrophage colony-stimulating factor (GM-CSF), tumor necrosis factor alpha (TNFα) and chemokine (C-X-C motif) ligand 8 (CXCL8)/IL-8, has been postulated. Treatment is based on the removal of the causative drug, supportive care, infection prevention and use of potent topical or systemic steroids. View Full-Text
Keywords: acute generalized exanthematous pustulosis; dermatology; skin; drug reaction acute generalized exanthematous pustulosis; dermatology; skin; drug reaction

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Feldmeyer, L.; Heidemeyer, K.; Yawalkar, N. Acute Generalized Exanthematous Pustulosis: Pathogenesis, Genetic Background, Clinical Variants and Therapy. Int. J. Mol. Sci. 2016, 17, 1214.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top